Stocks News

LAST PRICE
12.2900
TODAY'S CHANGE (%)
Trending Up0.2400 (1.9917%)

Bid / Lots
11.8500/ 2
Ask / Lots
12.5000/ 5
Open / Previous Close
12.0600 / 12.0500
Day Range
Low 11.8800
High 12.4800
52 Week Range
Low 3.0000
High 13.6600
Volume
391,395
above average

Search Criteria

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
Company	Country	Symbol

TD Direct Investing offers more research reports than any other discount brokerage in Canada. Provided from the industry's most trusted sources, our service includes timely, relevant information for the current trading day and comprehensive industry, sector, and insider trading reports for further analysis.

Open a New Account, or Login if you're a client.

News Volume Accessibility Table
Date	Index Fund Price vs. News Density
03/2	$11.73
03/3	$11.78
03/6	$11.78
03/7	$11.81
03/8	$11.53
03/9	$11.42
03/10	$11.39
03/13	$11.47
03/14	$11.71
03/15	$11.55
03/16	$11.76
03/17	$11.60
03/20	$11.50
03/21	$11.56
03/22	$11.73
03/23	$11.87
03/24	$12.03
03/27	$12.12
03/28	$12.10
03/29	$12.20
03/30	$12.05
03/31	$12.29

Mar 22, 2023
- Insider Buy: Merrimack Pharmaceuticals, from 4:16PM ET on Wednesday Mar 22, 2023 by MT Newswires
  4:16PM ET on Wednesday Mar 22, 2023 by MT Newswires
  Companies Mentioned: MACK
  04:16 PM EDT, 03/22/2023 (MT Newswires) -- Eric Andersen, Director, on March 21, 2023, executed a purchase for 160,590 shares in Merrimack Pharmaceuticals (MACK) for $1,849,997. Following the Form 4 filing with the SEC, Andersen has control over a t...
Mar 9, 2023
- BRIEF-Merrimack Reports Full Year 2022 Financial Results, from 4:41PM ET on Thursday Mar 09, 2023 by Thomson Reuters
  4:41PM ET on Thursday Mar 09, 2023 by Thomson Reuters
  Companies Mentioned: MACK
  March 9 (Reuters) - Merrimack Pharmaceuticals Inc:
  * MERRIMACK REPORTS FULL YEAR 2022 FINANCIAL RESULTS
  * MERRIMACK PHARMACEUTICALS INC - EXPECT THAT CA...
- Merrimack Reports Full Year 2022 Financial Results, from 4:40PM ET on Thursday Mar 09, 2023 by Business Wire
  4:40PM ET on Thursday Mar 09, 2023 by Business Wire
  Companies Mentioned: MACK
  Merrimack Pharmaceuticals, Inc. (Nasdaq: MACK) ("Merrimack" or the "Company") today announced its full year 2022 financial results for the period ended December 31, 2022.
  "We are encouraged by the results of the NAPOLI 3 trial as reported by Ipsen in November 2022 and the guidance that Ipsen has subsequently provided regarding its intention to file a supplemental New Drug Application with the U.S. Food and Drug Administration for Onivyde(R) in previously untreated patients with metastatic pancreatic ductal adenocarcinoma ("mPDAC"), which could lead to a potential future milestone payment from Ipsen" said Gary Crocker, CEO and Chairman of Merrimack's Board of Directors. "As a result of the exercise of stock options during the fourth quarter of 2022 and continued reductions in our operating expenses during 2022 we expect that our cash and cash equivalents as of December 31, 2022, will be sufficient to continue our operations beyond 2027, which we estimate to be the latest date when the longest-term potential Ipsen milestone may be achieved."

Mar 30, 2023
- Nkarta CFO Nadir Mahmood Resigns; Trial Update on Prospective Leukemia Treatment Set for Q2; Stock Rises, from 5:24PM ET on Thursday Mar 30, 2023 by MT Newswires
  5:24PM ET on Thursday Mar 30, 2023 by MT Newswires
  Companies Mentioned: NKTX
- BRIEF-Nkarta Announces Departure Of Chief Financial & Business Officer, from 4:08PM ET on Thursday Mar 30, 2023 by Thomson Reuters
  4:08PM ET on Thursday Mar 30, 2023 by Thomson Reuters
  Companies Mentioned: NKTX
- Nkarta Announces Departure of Chief Financial & Business Officer, from 4:01PM ET on Thursday Mar 30, 2023 by GlobeNewswire
  4:01PM ET on Thursday Mar 30, 2023 by GlobeNewswire
  Companies Mentioned: NKTX
- BRIEF-Citius Pharmaceuticals Advances Efforts To Spin Off Oncology Asset, from 10:18AM ET on Thursday Mar 30, 2023 by Thomson Reuters
  10:18AM ET on Thursday Mar 30, 2023 by Thomson Reuters
  Companies Mentioned: CTXR
- Citius Pharmaceuticals Advances Efforts to Spin Off Oncology Asset, I/ONTAK, into a Standalone Public Company, from 8:30AM ET on Thursday Mar 30, 2023 by PR Newswire
  8:30AM ET on Thursday Mar 30, 2023 by PR Newswire
  Companies Mentioned: CTXR
Mar 28, 2023
- Credit Suisse Lowers Acumen Pharmaceuticals' Price Target to $13 From $16, Updates Model to Reflect Q4 Actuals; Keeps Outperform Rating, from 8:42AM ET on Tuesday Mar 28, 2023 by MT Newswires
  8:42AM ET on Tuesday Mar 28, 2023 by MT Newswires
  Companies Mentioned: ABOS
- Acumen Pharmaceuticals Presents in vitro Human Neuron Model for Evaluating Binding of Amyloid Beta Oligomers in Alzheimer's Disease, from 8:00AM ET on Tuesday Mar 28, 2023 by GlobeNewswire
  8:00AM ET on Tuesday Mar 28, 2023 by GlobeNewswire
  Companies Mentioned: ABOS
Mar 27, 2023
- Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December 31, 2022 and Business Highlights, from 7:00AM ET on Monday Mar 27, 2023 by GlobeNewswire
  7:00AM ET on Monday Mar 27, 2023 by GlobeNewswire
  Companies Mentioned: ABOS
Mar 22, 2023
- Acumen Pharmaceuticals to Participate in Stifel 2023 Virtual CNS Days, from 4:01PM ET on Wednesday Mar 22, 2023 by GlobeNewswire
  4:01PM ET on Wednesday Mar 22, 2023 by GlobeNewswire
  Companies Mentioned: ABOS
Mar 20, 2023
- Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2022 Financial Results on March 27, 2023, from 4:01PM ET on Monday Mar 20, 2023 by GlobeNewswire
  4:01PM ET on Monday Mar 20, 2023 by GlobeNewswire
  Companies Mentioned: ABOS

Merrimack Pharmaceuticals Inc
NASDAQ:MACKUnited States

Search Criteria

Mar 22, 2023

Insider Buy: Merrimack Pharmaceuticals, from 4:16PM ET on Wednesday Mar 22, 2023 by MT Newswires

Mar 9, 2023

BRIEF-Merrimack Reports Full Year 2022 Financial Results, from 4:41PM ET on Thursday Mar 09, 2023 by Thomson Reuters

Merrimack Reports Full Year 2022 Financial Results, from 4:40PM ET on Thursday Mar 09, 2023 by Business Wire

Peers Headlines

Mar 30, 2023

Nkarta CFO Nadir Mahmood Resigns; Trial Update on Prospective Leukemia Treatment Set for Q2; Stock Rises, from 5:24PM ET on Thursday Mar 30, 2023 by MT Newswires

BRIEF-Nkarta Announces Departure Of Chief Financial & Business Officer, from 4:08PM ET on Thursday Mar 30, 2023 by Thomson Reuters

Nkarta Announces Departure of Chief Financial & Business Officer, from 4:01PM ET on Thursday Mar 30, 2023 by GlobeNewswire

BRIEF-Citius Pharmaceuticals Advances Efforts To Spin Off Oncology Asset, from 10:18AM ET on Thursday Mar 30, 2023 by Thomson Reuters

Citius Pharmaceuticals Advances Efforts to Spin Off Oncology Asset, I/ONTAK, into a Standalone Public Company, from 8:30AM ET on Thursday Mar 30, 2023 by PR Newswire

Mar 28, 2023

Credit Suisse Lowers Acumen Pharmaceuticals' Price Target to $13 From $16, Updates Model to Reflect Q4 Actuals; Keeps Outperform Rating, from 8:42AM ET on Tuesday Mar 28, 2023 by MT Newswires

Acumen Pharmaceuticals Presents in vitro Human Neuron Model for Evaluating Binding of Amyloid Beta Oligomers in Alzheimer's Disease, from 8:00AM ET on Tuesday Mar 28, 2023 by GlobeNewswire

Mar 27, 2023

Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December 31, 2022 and Business Highlights, from 7:00AM ET on Monday Mar 27, 2023 by GlobeNewswire

Mar 22, 2023

Acumen Pharmaceuticals to Participate in Stifel 2023 Virtual CNS Days, from 4:01PM ET on Wednesday Mar 22, 2023 by GlobeNewswire

Mar 20, 2023

Acumen Pharmaceuticals to Report Fourth Quarter and Year-End 2022 Financial Results on March 27, 2023, from 4:01PM ET on Monday Mar 20, 2023 by GlobeNewswire